Mycophenolate mofetil in the treatment of IgA nephropathy: A systematic review

Singapore Medical Journal

Volumn 49, Issue 10, 2008, Pages 780-785

  Hian, Roger Tan Choon ^a   Loh, P T ^a   Yang, W S ^a   Chan, C M ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Glomerulonephritis; IgA nephropathy; Mycophenolate mofetil; Nephropathy; Proteinuria

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ARTICLE; DRUG EFFECT; DRUG EFFICACY; GLOMERULONEPHRITIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; LEUKOPENIA; PROTEIN URINE LEVEL; PROTEINURIA; UNSPECIFIED SIDE EFFECT;

CREATININE; GLOMERULONEPHRITIS, IGA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY FAILURE, CHRONIC; MYCOPHENOLIC ACID; PLACEBOS; PROTEINURIA; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 54949140366     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Donadio J, Grande J. Ig A nephropathy. N Engl J Med 2002; 347:738-48.
2. D' Amcio G. Natural history of idiopathic IgA nephropathy: the role of clinical and histological prognostic factors. Am J Kidney Dis 2002; 36:227-37.
3. Galla JH. IgA nephropathy. Kidney Int 1995; 47:377-87.
4. Zatz R, Noronha IL, Fujihara CK. Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies. Am J Physiol Renal Physiol 2002; 283:F1167-75.
5. Bennett WM, Walke RG, Kincaid-Smith P. Treatment if IgA nephropathy with eicosapentanoic acid: A two-year prospective trial. Clin Nephrol 1989; 31:128-31.
6. Pettersson EE, Rekola S, Berglund L, et al. Treatment of IgA nephropathy with omega-3 polysaturated fatty acids: a prospective, double-blind, randomised study. Clin Nephrol 1994; 41:183-90.
7. Donadio JV Jr, Bergstralh EF, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994; 331:1194-9.
8. Donadio JV Jr, Larson TS, Bergstralh EJ, et al. A randomised trial of high dose compared with low dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 2001; 12:791-9.
9. Dillon JJ. Fish oil therapy for IgA nephropathy. Efficacy and interstudy variability. J Am Soc Nephrol 1997; 8:1739-44.
10. Rekola S, Bergstand A, Bucht H. Deterioration rate in hypertensive IgA nephropathy: Comparison of a converting enzyme inhibitor and beta blocking agents. Nephron 1991; 59:57-60.
11. Cattran D, Greenwood C, Ritchie S. Long-term benefit of angiotensin converting enzyme inhibitor therapy in patients with severe IgA nephropathy: a comparison to patients receiving treatment with other anti-hypertensive agents and patients receiving no therapy. Am J Kidney Dis 1994; 23:247-54.
12. Bannister K, Weaver A, Clarkson A, et al. Effect of angiotensin converting enzyme inhibitors and calcium channel blockers on progression of IgA nephropathy. Contrib Nephrol 1995;111:184-93.
13. Maschio G, Cagnoli L, Claroni F, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: A multicentre, randomised, placebo-controlled study. Nephrol Dial Transplant 1994; 9:265-9.
14. Russo D, Pisani A, Balletta MM, et al. Additive antiproteinuric effect of converting enzyme inhibitor and Losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33:851-6.
15. Samuels JA, Strippoli GFM, Craig JC, et al. Immunosuppressive agents for treating IGA nephropathy (Cochrane Review). In: The Cochrane Library, Issue 2, 2004.
16. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60:225-32.
17. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345:1321-5.
18. A blinded, randomised clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Tricontinental Mycophenolate Mofetil Study Group. Transplantation 1996; 61:1029-37.
19. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanism of action. Immunopharmocology 2000; 47:85-118.
20. Choi MJ, Gimenez, Briggs WA, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61:1098-114.
21. Zimmerman RF, Miller G, Appel GB, et al. Mycophenolate mofetil treatment of idiopathic membranous [abstract]. J Am Soc Nephrol 1998; 9:103A.
22. Chen X, Wu J, Tang L, et al. [A randomised control trial of mycophenolate mofetil treatment in severe IgA nephropathy]. Zhonghua Yi Xue Yuan Za Zhi 2002; 82:796-801. Chinese.
23. Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004; 65:1842-9.
24. Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005; 68:802-12.
25. Frisch G, Lin J, Rosenstock, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomised controlled trial. Nephrol Dial Transplant 2005; 20:2139-45.
26. Hogg RJ, Wyatt RJ. Scientific Planning Committee of the North American IgA Nephropathy Study. BMC Nephrol 2004; 5:3.
27. Dal Canton A, Amore A, Barbano G. One-year angiotensin-converting enzyme inhibition plus mycophenolate mofetil immunosuppression in the course of early IgA nephropathy: a multicenter, randomised, controlled study. J Nephrol 2005; 18:136-40.
28. Lai FM, Szeto CC, Choi PC, et al. Primary IgA nephropathy with low histologic grade and disease progression: Is there a "point of no return"? Am J Kidney Dis 2002; 39:401-6.
29. Fujuhara CK, De Lourdes Noronha I, Malheiro DM, et al. Combined mycophenolate mofetil and losartan therapy arrests established injury in remnant kidney. J Am Soc Nephrol 2000; 11:283-90.
30. Abbate M, Zoja C, Rottoli D, et al. Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein and complement-dependent interstitial inflammation in experimental renal disease. J Am Soc Nephrol 1999; 10:804-13.
31. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987; 64:709-27.
32. Branten AJ, du Buf-Vereijken PW, Vervloet M, Wetzels JF. Mycophenolate mofetil in idiopathic membranous neprhropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide. Am J Kidney Dis 2007; 50:248-56.
33. Ballarin J, Poveda R, Romero R, et al. Treatment of idiopathic membranous nephropathy with the combination of steriods, tacrolimus and mycophenolate mofetil: results of a pilot study. Nephrol Dial Transplant 2007; 22:3196-201.
34. Heering P, Braun N, Grabensee B, et al. Cyclosporin A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 2004; 43:10-8.
35. Goumenos DS, Tsagalis G, Brown CB, et al. Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study. Nephron Clin Pract 2006; 104:c83-4.